Table 3 Baseline and demographic characteristics of the two study cohorts: patients whose inhaled corticosteroid (ICS) device was switched (switched cohort) and the matched patients whose ICS device was not switched (control cohort)
From: Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control
Baseline Characteristic | Switched Cohort (n = 824) | Control Cohort (n = 824) | p Value For Comparison | |
|---|---|---|---|---|
Sex* | Female, n (%) | 445 (54%) | 445 (54%) | N/A |
Age* in yrs | Median (IQR) | 32 (15–50) | 33 (14–51) | 0.720** |
Smoking status,* n (%) | Non-smoker | 399 (48%) | 399 (48%) | N/A |
Smoker | 240 (29%) | 240 (29%) | ||
Ex-smoker | 54 (7%) | 54 (7%) | ||
Passive smoker | 20 (2%) | 20 (2%) | ||
Data missing | 111 (13%) | 111 (13%) | ||
Recorded rhinitis history,* n (%) | 144 (17%) | 144 (17%) | N/A | |
Oral corticosteroid courses/yr,* n (%) | 0 | 709 (86%) | 709 (86%) | N/A |
1 | 76 (9%) | 76 (9%) | ||
2 | 20 (2%) | 20 (2%) | ||
3–8 | 19 (2%) | 19 (2%) | ||
Hospitalized for asthma,* n (%) | 5 (0.6%) | 5 (0.6%) | N/A | |
Socioeconomic quintile, n (%) | Lowest | 309 (38%) | 189 (23%) | <0.001 § |
2nd | 49 (6%) | 111 (13%) | ||
3rd | 297 (36%) | 162 (20%) | ||
4th | 50 (6%) | 167 (20%) | ||
Highest | 119 (14%) | 192 (23%) | ||
SABA daily dose, † median (IQR) | 0.55 (0–1.64) | 0.82 (0.27–1.64) | <0.001** | |
Asthma consultations/yr | Median (IQR) | 0 (0–1) | 1 (0–2) | |
Range | 0–9 | 0–14 | ||
Asthma consultation rate, n (%) | 0 | 524 (64%) | 406 (49%) | <0.001** |
1 | 167 (20%) | 212 (26%) | ||
2 | 73 (9%) | 103 (13%) | ||
≥ 3 | 60 (7%) | 103 (13%) | ||
Recorded gastroesophageal disease, n (%) | 45 (5%) | 62 (8%) | 0.089 § | |
Recorded cardiovascular disease, n (%) | 33 (4%) | 48 (6%) | 0.087 § | |
Daily dose of ICS on index day, ‡ median (IQR) | 400 μg (400–800) | 400 μg (400–800) | 0.137** |